10% W/V Mannitol Intravenous Infusion Bp Infusion
Mannitol 20%
100mg/ml
Qatar Pharma
| Pack size | 500ml Plastic Bottle |
|---|---|
| Dispensing mode | POM |
| Source | QATAR |
| Agent | PHARMA STORES |
| Retail Price | 7.50 AED |
Available as:
Indications
10% W/V Mannitol Intravenous Infusion Bp Infusion is used for:
Chronic bronchitis, Cerebral oedema, Oliguric phase of renal failure, Raised intracranial pressure, Renal function testing, Transurethral prostatic resection
Adult Dose
Intravenous
Oliguric phase of renal failure
Adult: 50-100 g in a 24-hr period by IV infusion. Adjust rate of administration to maintain a urine flow of at least 30-50 mL/hr.
Cerebral oedema, Reduction of raised intraocular pressure
Adult: 0.25-2 g/kg by IV infusion given over 30-60 minutes.
Renal function testing
Adult: 0.2 g/kg infused over 3-5 min.
Child Dose
Intravenous
Edema
0.25-1 g/kg IV initially; maintenance dose of 0.25-0.5 g/kg IV q4-6hr
Anuria/Oliguria
Test dose: 0.2 g/kg IV over 3-5 minutes; not to exceed 12.5 g
Discontinue if no diuresis within 2 hr
Renal Dose
Administration
Contra Indications
Pulmonary congestion or oedema; intracranial bleeding; CHF; metabolic oedema with abnormal capillary fragility; anuria due to severe renal disease; severe dehydration.
Precautions
Hypervolaemia; urinary tract obstruction; check for signs of fluid and electrolyte imbalance. Should not be administered with whole blood. Pregnancy, lactation.
Pregnancy-Lactation
Pregnancy
Available case report data over decades of use have not identified drug- associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes
Drug crosses placenta and may cause fluid shifts that could potentially result in adverse effects in fetus; product should be given to pregnant woman only if clearly needed
Labor and delivery
Studies have not been conducted to evaluate effects on labor and delivery; exercise caution when administering product during labor and delivery
Animal data
No adverse developmental effects from mannitol reported in published animal studies; however, fluid shifts occurred in fetal ewes in response to maternal infusion of drug
Lactation
There are no data on presence of mannitol in either human or animal milk, effects on breastfed infant, or on milk production
Consider developmental and health benefits of breastfeeding along with mother’s clinical need for drug and any potential adverse effects on breastfed infant from drug or from underlying maternal condition
Interactions
Increased nephrotoxicity with ciclosporin.
Adverse Effects
Side effects of Mannitol 20% :
Fluid and electrolyte imbalance; acidosis (with high doses). Nausea, vomiting, thirst; headache, dizziness, convulsions, chills, fever; tachycardia, chest pain; blurred vision; urticaria and hypotension or hypertension; acute renal failure; skin necrosis; thrombophloebitis.
Mechanism of Action
Mannitol increases urinary output by inhibiting tubular reabsorption of water and electrolytes. It raises the osmotic pressure of the plasma allowing water to be drawn out of body tissues.
Note
10% W/V Mannitol Intravenous Infusion Bp 100mg/ml Infusion manufactured by Qatar Pharma. Its generic name is Mannitol 20%. 10% W/V Mannitol Intravenous Infusion Bp is availble in United Arab Emirates.
Farmaco UAE drug index information on 10% W/V Mannitol Intravenous Infusion Bp Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.
Some other brands of Mannitol 20% :
Infusion
Mannitol 20% W/V Bp
200mg/ml
Gulf Inject LLC
Infusion
Mannitol 10% W/V Bp
100mg/ml
Gulf Inject LLC
Infusion
20% W/V Mannitol Intravenous Infusion Bp
200mg/ml
Qatar Pharma
Infusion
20% W/V Mannitol Intravenous Infusion Bp
200mg/ml
Qatar Pharma
Infusion
MANNITOL INJECTION 20% USP
200mg/ml
Kuwait Saudi Pharmaceutical Industries Co. (KSPICO)